Depression

Kentucky

34 Depression Trials near Kentucky

Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
Active on Power

MM120 for Depression

Cincinnati, Ohio
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

140 Participants Needed

Lumateperone for Pediatric Bipolar Depression

Cincinnati, Ohio
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

384 Participants Needed

Lumateperone for Major Depressive Disorder

Cincinnati, Ohio
This trial is testing lumateperone, a medication that may help people with depression who haven't improved with other treatments. The study includes patients diagnosed with Major Depressive Disorder who haven't responded well to their current antidepressants. Lumateperone works by balancing brain chemicals that affect mood, potentially improving depressive symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

470 Participants Needed

Antidepressants for Anxious Depression

Cincinnati, Ohio
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 50

84 Participants Needed

JNJ-89495120 for Depression

Cincinnati, Ohio
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64

124 Participants Needed

Centanafadine for Depression

Cincinnati, Ohio
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD). The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

336 Participants Needed

BI 1569912 for Depression

Cincinnati, Ohio
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants are put into 4 groups randomly, which means by chance. Three of the 4 groups take different doses of BI 1569912 and 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2.5 months. During this time, they visit the study site at least 7 times. At the visits, doctors and their staff ask participants about their depression symptoms. At the end of the study, the results are compared between the groups to see whether the treatment works. The doctors also regularly check the general health of participants and take note of any unwanted effects.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65

224 Participants Needed

eCBT for Depression

Louisville, Kentucky
This trial will test online therapy sessions for depression in rural West Virginia and Kentucky. The therapy can be done alone or with support from a remote coach. It aims to improve mental health by changing negative thoughts and behaviors, with coaches providing extra help in guided sessions.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

3360 Participants Needed

Well-Being Training for Educator Stress

Louisville, Kentucky
This study is a randomized controlled trial (RCT) of the four-week Healthy Minds Program (HMP) app Foundations training in employees of Jefferson County Public Schools (JCPS) in Louisville, KY. The study will enroll 1300 JCPS employees. After completing the baseline assessment, participants will be randomly assigned to the intervention (i.e., the Healthy Minds Program App) or to a "Choice" control condition. HMP assigned participants will receive instructions and support in downloading and activating the app. Choice assigned participants will receive a list of resources that are focused on the science of well-being and happiness consisting of TED talk videos and books. 10 copies of each suggested book will be available for participants to check out. TED talk video links will be provided and are free to watch. Each week during the 4-week intervention period, participants in both conditions will complete the same weekly set of measures. Within two-weeks following the end of the intervention period, all participants will complete the post-test assessment. Approximately five to six months following post-test, participants will complete the follow-up assessment. In addition to study team collected data, the research team will receive from the district multiple years of student records (e.g., standardized assessments, attendance, disciplinary referrals) linked to teachers (teachers only, not other categories of employees who choose to participate). The researchers predict that participants assigned to the intervention will demonstrate significantly reduced anxiety and depressive symptoms and significantly improved well-being after the intervention, and these improvements will persist at the follow-up (primary outcomes). It is hypothesized that baseline participant characteristics and early experience of the intervention will predict treatment adherence, study drop-out and outcomes, and that treatment engagement will moderate outcomes. In addition, the investigators predict that intervention period improvements on well-being skills assessed weekly will mediate long-term improvements on primary outcomes.

Trial Details

Trial Status:Completed
Trial Phase:Unphased

829 Participants Needed

Cariprazine for Bipolar Disorder in Youth

Cincinnati, Ohio
This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:10 - 17

380 Participants Needed

Seltorexant for Depression

Cincinnati, Ohio
This trial is testing seltorexant to see if it can help people with depression and insomnia who haven't improved with their current antidepressants. Seltorexant aims to improve mood and sleep by acting on certain brain receptors.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

752 Participants Needed

VNS for Bipolar Depression

Huntington, West Virginia
This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

6800 Participants Needed

Aticaprant + Antidepressant for Depression

Cincinnati, Ohio
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor \[SSRI\] or serotonin-norepinephrine reuptake inhibitor \[SNRI\]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 64

660 Participants Needed

Duloxetine vs Escitalopram for Depression

Cincinnati, Ohio
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:12 - 17

60 Participants Needed

Positive Psychosocial Intervention for Dementia

Jackson, Ohio
The goal of this clinical trial is to test the feasibility of the Individualized Positive Psychosocial Interaction (IPPI) with 108 nursing home residents living with dementia and distress or depressive symptoms. The main questions it aims to answer are: •is it feasible to deliver the IPPI and track impact through data collected in the electronic medical records. Care partners will engage eligible residents in 2 brief preference-based IPPIs per week over the course of 6 months.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

135 Participants Needed

Pramipexole vs Escitalopram for Depression in HIV

Cincinnati, Ohio
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

186 Participants Needed

Rumination-Focused Cognitive Behavioral Therapy for Depression

Louisville, Kentucky
Many people know that a poor diet, exercise, smoking, and alcohol use cause heart disease. However, a less known factor that increases the risk of heart disease is depression. In addition, heart disease can also make depression worse. Almost half of American adults have some form of heart disease. Patients with low income are at an even greater risk. The circular relation between depression and heart disease raises the question of whether or not there are factors that lead to both. Attacking a factor that affects both depression and heart disease could help prevent them both. One such factor is rumination which is when someone tends to have repeated negative thoughts that loop without end. This loop in turn tears and wears down the body over time, making the person be at risk for heart disease and depression. Rumination-Focused Cognitive Behavioral Therapy (RFCBT) is a tool that targets rumination and, by doing so, reduces the risk for depression. While research has shown RFCBT helps to reduce or stop the loop that leads to depression, this project will further look at the effect of RFCBT on measures of heart health persons with low income.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

9 Participants Needed

Single-Session Intervention for Suicidal Thoughts

Lexington, Kentucky
Across multiple models of suicide risk, hopelessness and perceptions of social relatedness (i.e., lack of social connection/thwarted belongingness, perceived burdensomeness) have emerged as candidate mechanisms that maintain STBs. Although these mechanisms have garnered strong empirical support in predicting STBs, there has been virtually no integration with interventions aimed for individuals at acute risk for suicide. Thus, the overarching goal of the present proposal is to evaluate a mechanism-focused intervention that explicitly targets two core mechanisms implicated in the maintenance of STBs: hopelessness and negative perceptions of social relatedness. Given that the period immediately following hospital discharge presents the highest risk for suicide attempts and up to 70% of patients admitted for a suicide attempt do not attend their first outpatient appointment, the intervention will be evaluated on an inpatient unit. Additionally, most of the extant interventions for STBs are administered across multiple sessions (i.e., 4 sessions and up to one year); however treatments of this length are unlikely to be feasible in acute care settings. Fortunately, very brief suicide prevention interventions, are effective in reducing future suicide attempts and increasing the likelihood of attending follow-up treatments. Additionally, single-session interventions (not suicide specific) have been shown to reduce hopelessness immediately and at a one-month follow-up. The present study is an RCT comparing a novel Single Session Mechanism Focused Intervention (SSMFI) for STBs to treatment-as-usual (TAU) on a psychiatric inpatient unit for patients admitted for suicidal ideation or attempt. The engagement of the putative processes (hopelessness and negative perceptions of social relatedness) that maintain STBs will be assessed, along with the feasibility and acceptability of SSMFI for STBs on an inpatient psychiatric unit.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

128 Participants Needed

Theta Burst Stimulation for Depression and Autism

Cincinnati, Ohio
Evaluate the efficacy of accelerated theta burst stimulation (aTBS) in reducing depressive symptoms in autism spectrum disorder (ASD)

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:13 - 26

24 Participants Needed

Lifestyle Intervention for Heart Disease Risk

Cincinnati, Ohio
This research seeks to improve the Midlife Black Women's Stress Reduction and Wellness Intervention (B-SWELL), a program designed to lower heart disease risk in midlife Black women. The B-SWELL leverages stress reduction to facilitate the adoption and adherence to healthier lifestyle behaviors. This research study will use choice to increase engagement and minimize the effect of social determinants of health on research participation among midlife Black women. A comparative clinical trial will be conducted. Midlife Black women (ages 45-64) who reside in the Greater Cincinnati area will be recruited for participation. Women are eligible if they self-identify as Black/ African American, are between the ages of 45-64, and are willing to commit to the requirements of the study (e.g., attend 8 weekly sessions and 4 phone interviews). Participants will be randomly placed (like the flip of a coin) into either the B-SWELL or WE group. Both the B-SWELL and WE groups are 8-week programs that focus on healthy lifestyle behaviors and heart disease awareness. Women will have the choice to participate in person or virtually. Survey phone interviews will be conducted at baseline, 8-, 12-, and 16-weeks. Data collected will provide information about adherence, healthy lifestyle behaviors, and cardiovascular health. Heart health will be measured using the American Heart Association's Life's Essential 8 metric. Outcome measures include heart disease awareness, Life's Essential 8 score, stress, self-efficacy, depressive symptoms, and symptoms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:45 - 64
Sex:Female

64 Participants Needed

Why Other Patients Applied

"Tried Lexapro, Wellbutrin and another (forget which). Surgical accident destroyed my mental nerve and left me in chronic pain, depression, and anxiety. That was 15 years ago. Disabled and retired. I'm tired of this."

IH
Depression PatientAge: 73

"I've been struggling with alcoholism and depression on-and-off for about 12 years. I have heard of people have good outcomes for various mental health issues after using psilocybin but would not be willing to try it without a doctor's care. So I'm applying to a trial. "

QJ
Depression PatientAge: 60

"I have tried several different drugs and nothing seems to help really. I'm hoping this trial could give me my life back. I haven't tried anything like psilocybin yet... fingers crossed."

MT
Anxiety PatientAge: 59

"I've been through a substance abuse program three times. Clearly, it's not working. I need to try something totally different and new to deal with my depression (plus alcohol usage) once and for all. I did some research on psilocybin and want to try."

QP
Depression PatientAge: 55

"I have struggled with depression since I was a child. I have experienced about more than 6 major depressive episodes lasting at least 4 months since I was 7 years old. I have tried talk therapy, a plethora of medication, and nothing has worked long term. Medication and talk therapy helps me manage and reduce the length of depressive episodes but I am in search for alternative treatments. My depression has made completing a bachelors degree a major challenge."

UD
Depression PatientAge: 25

Behavioral Health Intervention for Pediatric Injury

Lexington, Kentucky
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This proposal builds on prior research from the investigative team to test a technology-assisted, stepped care behavioral health intervention for children (\<12 years) and their caregivers after PTI, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), via a hybrid type I effectiveness-implementation trial with 348 families randomly assigned to CAARE (n=174) vs. guideline-adherent enhanced usual care (EUC) (n=174).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

348 Participants Needed

Emotion Regulation Strategies for Emotional Regulation Issues

Lexington, Kentucky
This trial is testing whether different emotion management techniques help people reduce their negative emotions more effectively. It aims to find out which method works best for improving emotional well-being.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

390 Participants Needed

Psychological Intervention for Parents of Babies with Congenital Heart Defects

Cincinnati, Ohio
Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

104 Participants Needed

Aticaprant for Depression

Cincinnati, Ohio
This trial is testing if aticaprant can help adults with major depressive disorder who haven't responded well to current antidepressants. The medication works by targeting brain chemicals to improve mood and pleasure.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:18 - 64

350 Participants Needed

TMS vs ECT for Depression

Lexington, Kentucky
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use. These barriers include procedure tolerability, cognitive side effects, financial burden, and unreliable social support to accompany patients for these treatments. On the other hand, a different modality of noninvasive neuromodulation called transcranial magnetic stimulation (TMS) can be performed in the outpatient setting and does not need anesthesia. The likelihood of cognitive adverse effects with TMS is much lower than with ECT. Our clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder. This will be a patient-preference clinical trial, with patients offered the choice to initiate maintenance TMS versus maintenance ECT after their index ECT sessions for treatment-resistant depression. There will be no randomization or placebo involved in this study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

30 Participants Needed

Coping Skills Program for Lupus

Cincinnati, Ohio
This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 22

196 Participants Needed

Health Screening and Referral for Premature Birth

Cincinnati, Ohio
Up to a quarter of the families with preterm infants have unmet social needs, such as housing or job insecurity, which represent adverse social determinants of health (SDOH). Preterm infants are especially vulnerable to the social conditions they grow up in, with sustained impacts on function across multiple organ systems. The goal of this study is to translate an established model of SDOH screening and referral from the outpatient setting to the NICU, thereby maximizing the potential to offset the effects of adverse SDOH on vulnerable mother-preterm infant dyads.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Sex:Female

882 Participants Needed

Psilocybin for Major Depressive Disorder - TRD

Cincinnati, Ohio
This trial is testing COMP360, a new treatment for adults who have not responded to other depression treatments. Participants will receive one of three doses of COMP360 along with psychological support. The goal is to see if this combination can help improve their depression symptoms.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

568 Participants Needed

Ecopipam for Tourette Syndrome

Louisville, Kentucky
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:6+

150 Participants Needed

ROSE-010 for Obesity

Cincinnati, Ohio
The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity. The secondary objectives of this study are the following: * To assess the efficacy of ROSE-010 on hunger; * To assess the efficacy of ROSE-010 on satiety; * To assess the efficacy of ROSE-010 on prospective consumption; * To assess the efficacy of ROSE-010 on desire to eat; * To assess the efficacy of ROSE-010 on palatability; * To characterize the pharmacokinetics (PK) of ROSE-010 following subcutaneous (SC) administration on Day 1 and Day 7; and * To evaluate safety and tolerability of SC administrations of ROSE-010 to overweight and obese subjects.

Trial Details

Trial Status:Not Yet Recruiting
Age:18 - 65
Sex:Female

40 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Depression clinical trials in Kentucky pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Depression clinical trials in Kentucky work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Depression trials in Kentucky 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Kentucky for Depression is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Kentucky several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Depression medical study in Kentucky?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Depression clinical trials in Kentucky?

Most recently, we added Pramipexole vs Escitalopram for Depression in HIV, Behavioral Health Intervention for Pediatric Injury and Mirvetuximab Soravtansine for Ovarian Cancer to the Power online platform.

What are the current treatment options for depression?

Doctors use a stepped-care approach. First, most people try evidence-based talk therapy (such as CBT or interpersonal therapy), an antidepressant medicine (SSRIs are typical), or both, while also improving sleep, exercise and diet. If symptoms persist, the next “step” is to add or switch treatments—e.g., combining two medicines, adding lithium or an antipsychotic, or using brain-stimulation methods like transcranial magnetic stimulation or, for severe cases, electroconvulsive therapy; newer options such as esketamine nasal spray are reserved for treatment-resistant depression. Working with a clinician to review progress every few weeks and adjust the plan is key to finding the right mix.

When is depression considered severe?

Doctors call a depressive episode “severe” when almost all of the nine core symptoms are present at high intensity, the person’s daily life has largely shut down (can’t work, study, or manage self-care), or there are high-risk features like active suicidal thoughts, a recent attempt, or hallucinations/false beliefs. On common checklists this usually means a PHQ-9 score of 20 or higher, and it signals the need for urgent, comprehensive care—often a combination of medication, psychotherapy, and sometimes hospitalization. If you or someone you know reaches this point, treat it as an emergency and contact a mental-health professional or call/text 988 (USA) or your local crisis line right away.

Is it possible to never be depressed again?

Some people have a single episode of depression and stay well, but the risk of another episode is higher if you stop treatment too soon, have had several episodes before, or still have mild symptoms. You can greatly lower that risk by continuing the treatment that got you better for at least 6–12 months, learning relapse-prevention skills in CBT or mindfulness therapy, keeping regular sleep, exercise, and social routines, and checking in early with a professional if warning signs return. In short, there is no iron-clad guarantee you’ll never be depressed again, but staying on maintenance care and a healthy lifestyle makes long-term wellness much more likely.

What are the top 3 symptoms of depression?

Doctors look first for three core signs: 1) a low or hopeless mood that hangs around most of the day, nearly every day; 2) a marked loss of interest or pleasure in things you used to enjoy (called anhedonia); and 3) big changes in body energy—feeling drained, sleeping or eating far more or less than usual. If any of these have lasted two weeks or longer, it’s time to talk with a health professional, because other symptoms can pile on and treatment works best when started early.

Is depression a chemical imbalance?

No—depression can’t be pinned on one missing brain chemical. Research shows it arises from a mix of factors: how your brain circuits and several neurotransmitters work, your genes, long-term stress, and life circumstances all interact. Because causes differ from person to person, the most effective care is usually a combination of approaches—medication when needed, talking therapies, and lifestyle changes—worked out with your clinician.

How many people have untreatable depression?

Doctors call “untreatable” depression “treatment-resistant depression,” meaning the person has not improved after trying at least two suitable antidepressants. Large studies show this applies to roughly one-quarter to one-third of people with major depression—about 2–3 % of adults overall, or roughly 5–8 million U.S. adults in any given year. Importantly, many still respond to other options such as medication combinations, ketamine/esketamine, transcranial magnetic stimulation, or electroconvulsive therapy.

How to get out of deep depression?

Think of recovery as two tracks that run side-by-side. Track 1: get professional help right away—if you ever feel unsafe call 988 (or your local hotline), and with a clinician discuss proven treatments such as CBT, antidepressant medicine, and, when needed, newer options like ketamine, transcranial magnetic stimulation or electroconvulsive therapy. Track 2: reinforce the medical plan daily with mood-boosting basics—consistent exercise, regular sleep, balanced meals, limited alcohol or drugs, and time with supportive people—because these habits make the treatments work better and give you small, sustainable lifts while you heal.

Why is depression so hard to treat?

Depression is hard to treat because it isn’t a single disease—each person’s symptoms arise from a unique blend of brain chemistry, genetics, stress, medical issues, and life circumstances—so one-size-fits-all therapies rarely work. Without a blood test to guide choices, clinicians must try treatments sequentially, and roughly one-third of people need several steps or a combination of medication, talk therapy, lifestyle changes, or newer options like ketamine or magnetic stimulation before they feel well. The encouraging news is that persistence with a systematic plan and attention to sleep, exercise, and co-existing conditions allows most patients to eventually reach full recovery.

What are unhealthy coping mechanisms for depression?

Unhealthy coping means doing things that give quick relief but actually deepen depression—common examples include using alcohol or other drugs, overeating or not eating, oversleeping or endless screen-scrolling to avoid feelings, cutting or other self-harm, harsh self-talk and rumination, and withdrawing from friends or lashing out at them. These behaviors worsen mood, relationships, and safety; if you notice yourself relying on them, reach out to a trusted person or mental-health professional (or call your local crisis line) and ask about safer skills such as problem-solving steps, scheduled activity, or therapy.

Is it OK to have clinical depression?

Yes—having clinical depression isn’t a personal failing; it’s a common medical illness, and recognising it is the first step toward feeling better. What isn’t OK is to face it alone, because untreated depression can worsen and raise the risk of other problems, whereas most people improve with timely care such as talk therapy, medication, or a combination. If symptoms last more than two weeks or include thoughts of self-harm, book a visit with a primary-care doctor or mental-health professional and, in crisis, call 988 (U.S.) or your local emergency number—effective help and recovery are the norm when treatment is started.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Triple-Negative Breast Cancer Clinical Trials

88 Colorectal Cancer Trials near San Antonio, TX

Top Clinical Trials near Irving, TX

Top Treatment for Oxytocin Clinical Trials

156 Clinical Paid Trials near Arizona

190 Clinical Trials near Hodges, SC

Top Orthopedic Clinical Trials

Top Clinical Trials near Oakland, CA

Top Colorectal Cancer Clinical Trials near Phoenix, AZ

Top Clinical Trials near Coronado, CA

Top Fibroids Clinical Trials

Top Alcohol Related Disorders Clinical Trials

By Trial

Nipocalimab for Myasthenia Gravis

Anakinra for Leukemia

Ear Stimulation for Ehlers-Danlos Syndrome

Brain-Machine Interface for Quadriplegia

Mosunetuzumab for Follicular Lymphoma

Hyaluronic + Corticosteroid Injections and Physical Therapy for Hip Issues

Erdafitinib for Castration-Resistant Prostate Cancer

CanCEASE + Health Navigator for Smoking Cessation

Capsaicin Patch for Peripheral Neuropathy

Medically Tailored Meals for Heart Failure

PVX-410 + Pembrolizumab for Advanced Breast Cancer

Microwave Ablation + Prostate Resection for Prostate Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial